SENGROVI Trademark

Trademark Overview

On Wednesday, May 8, 2019, a trademark application was filed for SENGROVI with the United States Patent and Trademark Office. The USPTO has given the SENGROVI trademark a serial number of 79260654. The federal status of this trademark filing is REGISTERED as of Tuesday, December 17, 2019. This trademark is owned by Novo Nordisk Health Care AG. The SENGROVI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of hormonal disorders
sengrovi

General Information

Serial Number79260654
Word MarkSENGROVI
Filing DateWednesday, May 8, 2019
Status700 - REGISTERED
Status DateTuesday, December 17, 2019
Registration Number5934727
Registration DateTuesday, December 17, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 1, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of hormonal disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 18, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNovo Nordisk Health Care AG
Party Type30 - Original Registrant
Legal Entity Type25 - NOT AVAILABLE
AddressCH
Party NameNovo Nordisk Health Care AG
Party Type20 - Owner at Publication
Legal Entity Type25 - NOT AVAILABLE
AddressCH
Party NameNovo Nordisk Health Care AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Trademark Events

Event DateEvent Description
Thursday, June 13, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, June 18, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, June 22, 2019APPLICATION FILING RECEIPT MAILED
Monday, July 15, 2019ASSIGNED TO EXAMINER
Thursday, July 25, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, July 31, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, July 24, 2019NON-FINAL ACTION WRITTEN
Wednesday, August 7, 2019ASSIGNED TO LIE
Tuesday, August 13, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 13, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 20, 2019REFUSAL PROCESSED BY MPU
Tuesday, August 20, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, September 6, 2019REFUSAL PROCESSED BY IB
Wednesday, September 11, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, September 18, 2019NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Thursday, August 29, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 18, 2019NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, October 1, 2019PUBLISHED FOR OPPOSITION
Tuesday, October 1, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Saturday, October 5, 2019NOTIFICATION PROCESSED BY IB
Tuesday, December 17, 2019REGISTERED-PRINCIPAL REGISTER
Tuesday, March 17, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, March 28, 2020FINAL DISPOSITION PROCESSED
Saturday, March 28, 2020FINAL DISPOSITION NOTICE SENT TO IB
Friday, April 17, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, August 6, 2021CHANGE OF NAME/ADDRESS REC'D FROM IB
Sunday, November 21, 2021NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, December 17, 2024COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

Related Keywords

sengrovi disorders hormonal treatment preparations pharmaceutical